Ethyl pyruvate exerts combined anti-inflammatory and anticoagulant effects on human monocytic cells

Thrombosis and Haemostasis

Volumn 96, Issue 6, 2006, Pages 789-793

  van Zoelen, Marieke A D ^a   Bakhtiari, Kamran ^a   Dessing, Mark C ^a   van't Veer, Cornelis ^a   Spek, C Arnold ^a   Tanck, Michael ^a   Meijers, Joost C ^a   van der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Ethyl pyruvate; Lipopolysaccharide; Sepsis; THP 1 monocytic cells; Tissue factor

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; PYRUVIC ACID ETHYL ESTER; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING; CELL ACTIVITY; CELL CULTURE; CELL STIMULATION; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; SEPSIS;

ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; BLOOD COAGULATION; CELL LINE; CHEMOKINES, CC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIPOPOLYSACCHARIDES; MONOCYTES; PYRUVATES; RNA, MESSENGER; THROMBIN TIME; THROMBOPLASTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845358007     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-07-0393     Document Type: Article

References (15)

1. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997; 112: 235-43.
2. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-92.
3. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
4. Ulloa L, Ochani M, Yang H, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002; 99: 12351-6.
5. Sims CA, Wattanasirichaigoon S, Menconi MJ, et al. Ringer's ethyl pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats. Crit Care Med 2001; 29: 1513-8.
6. Uchiyama T, Delude RL, Fink MP. Dose-dependent effects of ethyl pyruvate in mice subjected to mesenteric ischemia and reperfusion. Intensive Care Med 2003; 29: 2050-8.
7. Tawadrous ZS, Delude RL, Fink MP. Resuscitation from hemorrhagic shock with Ringer's ethyl pyruvate solution improves survival and ameliorates intestinal mucosal hyperpermeability in rats. Shock 2002; 17: 473-7.
8. Yang R, Gallo DJ, Baust JJ, et al. Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol 2002; 283: G212-21.
9. Sappington PL, Fink ME, Yang R. et al. Ethyl pyruvate provides durable protection against inflammation-induced intestinal epithelial barrier dysfunction. Shock 2003; 20: 521-8.
10. Song M, Kellum JA, Kaldas H, et al. Evidence that glutathione depletion is a mechanism responsible for the anti-inflammatory effects of ethyl pyruvate in cultured lipopolysaccharide-stimulated RAW 264.7 cells. J Pharmacol Exp Ther 2004; 3W 307-16.
11. Han Y, Englert JA, Yang R, et al. Ethyl pyruvate inhibits nuclear factor-kappaB-dependent signaling by directly targeting p65. J Pharmacol Exp Ther 2005; 312: 1097-105.
12. Maris NA, de Vos AF, Dessing MC, et al. Anti-inflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med 2005; 172: 878-84.
13. Ollivier V, Hammal S, Ameziane N, et al. Modulation of tissue factor expression by rapamycin and FK-506 in lipopolysaccharide-stimulated human monorruclear cells and serum-stimulated aortic smooth muscle cells. Thromb Haemost 2005; 94: 46-52.
14. Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006; 26: 456-61.
15. Miyaji T, Hu X, Yuen PS, et al. Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int 2003; 64: 1620-31.